5 Medtech Stocks to Seize Major Growth

Veeva Systems

• Market value: $46.4 billion
• Analysts' average long-term (LT) earnings growth rate: 18.2%

Cloud computing and software-as-a-service (SaaS) applications have already revolutionized business, finance and entertainment. Veeva Systems (VEEV, $299.01) is doing the same for healthcare.

Founded by former Salesforce.com (CRM) executive Peter Gassner, VEEV has used the SaaS approach to produce various applications for the life sciences and biotech industries, drug producers and hospitals. These cloud solutions include everything from collecting trial data during drug development, customer management services and even ongoing risk management tools for drugs in production. Nearly a thousand clients use VEEV's software, including large-cap firms like Eli Lilly (LLY) and Moderna (MRNA).

One win for Veeva is that healthcare is a very regulated sector. The Food and Drug Administration (FDA) and other international regulatory groups require plenty of data and compliance to get drugs to market and keep them there. Veeva's products make these record-keeping and compliance requirements simple and easy.

This creates plenty of stickiness with its revenues. Just over 80% of its annual revenue for fiscal 2021 came from subscription services. Perhaps even better is that Veeva has been successful in transitioning its clients into other products. In fiscal 2021, VEEV saw a 33% year-over-year jump in revenues as it added new clients and moved older ones into extra products.

What is exciting for Veeva and its potential investors is that the company actually makes money. For the second quarter of fiscal 2022, net income clocked in at $108.9 million. This was a 16.3% year-over-year increase. Cash flows from operations were robust, as well.

As far as medical technology stocks go, this one is in a must-have niche for drug developers.

DexCom

• Market value: $52.5 billion
• Analysts' average LT earnings growth rate: 17.2%

There's a major epidemic that has swept across the world: diabetes. According to the latest numbers from the Centers for Disease Control and Prevention (CDC), more than 34.2 million people of all ages in the U.S. had diabetes in 2018. That's nearly 10.5% of the total population.

Globally, the International Diabetes Federation estimates that the number of adults with diabetes in 2019 was roughly 463 million. Managing that burden is a major endeavor and medical technology is helping on that front.

One win comes from continuous glucose monitoring (CGM). Here, a sensor is placed on a patient's body and is able to wirelessly send real-time glucose numbers to devices like smartphones and smartwatches. This eliminates the need for painful finger pricks and allows diabetes patients to quickly identify trends and make decisions on needed treatments.

There are a few medtech stocks in the CGM sector, but one of the fastest growing is DexCom (DXCM, $542.23).

DXCM created its first CGM product in 2006 and its latest iteration, the G6, was launched in 2018. The beauty of this device is that it can be paired with an insulin pump to help users more easily manage their diabetes.

Dexcom's strong presence in the CGM market is seen in its financial results. In the second quarter, the company saw a 32% jump in sales to $595.1 million versus a year ago. "Strong new customer additions continue to be the primary driver of revenue growth as awareness of real-time CGM increases," the company noted in its earnings press release.

There's plenty of growth potential, as well. CGM is still in its infancy here in the U.S. and abroad. And while originally designed as a product for Type-1 diabetes, new studies have suggested that CGM has profound effects on Type-2 diabetes care. This could lead to plenty of future sales for Dexcom.

Abiomed

• Market value: $16.0 billion
• Analysts' average LT earnings growth rate: 12.9%

The best medtech stocks use technology to improve processes or reduce the risk to patients. Abiomed (ABMD, $353.53) is a prime example of both.

Many patients needing heart surgery will use a percutaneous coronary intervention (PCI), or, as it was formerly called, angioplasty with stent. Heart surgery is very risky for even the healthiest of patients. But for those who have undergone some major cardiovascular event, surgery can be life-threatening. This is where ABMD comes in.

Abiomed's prime product is the Impella series of heart pumps. These devices help patients undergoing PCI or other heart-related surgeries while reducing risks. The Impella is a minimally invasive device and helps keep blood pressure and blood flow normal during surgery. It also takes the strain off of the heart. Impella pumps are removed after surgery.

Given that heart disease is the number one cause of death in the U.S., ABMD's products are very much in demand. Since 2005, Abiomed's sales have grown at a compound annual growth rate (CAGR) of 25% per year.

An added bonus: ABMD has been profitable since 2012. And with no debt on its balance sheet, the firm's cash balance has exploded over the years. At the end of fiscal 2021, Abiomed had $848 million in cash and investments on its balance sheet – up 30% on a year-over-year basis. That gives it a lot of firepower for research and development.

At 55x forward earnings, ABMD isn't cheap. But given the addressable market and its historic rate of revenue growth, that valuation may just be worth it for this medtech superstar.

Teladoc Health

• Market value: $21.3 billion
• Analysts' average LT earnings growth rate: N/A

Another plus for medical technology stocks is their ability to reduce costs and time for both consumers and enterprise customers. Take for instance Teladoc Health (TDOC, $133.72).

TDOC is the leading player in the growing field of telemedicine. Users can log in to Teladoc's cloud via a number of devices and speak with a doctor or physician's assistant in real-time, 24/7. Patients can get a diagnosis, requests for referrals or additional testing and they can even order prescriptions. Additionally, the company added programs that send remote monitoring devices, like blood pressure cuffs, to its users in order to get accurate data before Primary Care appointments.

Both patients and employers like the idea. Use of TDOC's services exploded during the pandemic when traditional doctor's offices were reducing the number of patients seen. Moreover, employers have continued to add Teladoc as part of their benefits packages. Since 2016, revenues have grown by a 70% CAGR, while the number of visits has grown 40% annually.

There's still room for additional growth. Teladoc recently launched myStrength Complete, a full-service mental health suite that allows users to access therapists and psychiatrists. New deals with Dexcom, Microsoft (MSFT) and health insurers are designed to add revenues and complimentary products to its mix.

The one caveat to TDOC is that it has yet to turn a profit, so the stock is very much a revenue play at this point. But given its leadership position, first-mover advantage and scope, profits could start materializing sooner rather than later.

And Wall Street pros are certainly bullish on the name, per S&P Global Market Intelligence. The consensus recommendation among the 29 analysts following the stock is Buy, while the average price target is $197.65, representing expected upside 47.8% over the next 12 months or so.

Illumina

• Market value: $70.2 billion
• Analysts' average LT earnings growth rate: 25.1%

One of the latest trends in drug development happens to be products that use gene sequencing. From custom cancer treatments and those drugs curing rare genetic diseases to diagnostics and testing, gene sequencing makes it happen. And much of that sequencing happens on machines produced by Illumina (ILMN, $448.85).

ILMN is one of the leaders in so-called next-generation sequencing. Skipping the science lecture, next-gen sequencing allows researchers to look at entire genomes or targeted regions of DNA or RNA quickly and at a lower cost than older methods. That means the science that used to take months to do could possibly be done in a day.

Both drug developers and university researchers continue to see the benefit in owning Illumina products, while hospitals, doctor's offices and clinics are now using sequencing for diagnostic testing. The next-generation sequencing market is expected to reach $24.2 billion by 2026, and ILMN is well-positioned to capitalize on that growth.

The firm uses the classic razor-blade model. The sequencers themselves aren't cheap to begin with, but where the Illumina makes its real money is in selling the blades, or, in this case the reagents, flow cells and microarrays. These items are needed to make the sequencer run and they get used up in the process.

In the second quarter, these sorts of consumables made up about 62.5% of Illuminia's total revenue – and sales for them were up 82% year-over-year. ILMN is also very profitable, with adjusted Q2 earnings per share tripling to $1.87 from the year prior. Plus, the company has plenty of free cash flow (FCF), which is the cash remaining after a company has paid its expenses, interest on debt, taxes and long-term investments to grow its business. In the second quarter, Illumina's FCF clocked in at $209 million.

There is significant growth potential for ILMN, too. New diagnostic testing kits, continued genetic drug research and its pending buyout of multi-cancer early detection firm Grail will help boost revenues and profits down the road.